|
|
 Previous Article | Table of Contents | Next Article 
Blood, Vol. 94 No. 12 (December 15), 1999:
pp. 4220-4232
Variant Genotypes of the Low-Affinity Fc Receptors in Two Control
Populations and a Review of Low-Affinity Fc Receptor Polymorphisms
in Control and Disease Populations
Thomas Lehrnbecher,
Charles B. Foster,
Shaoxian Zhu,
Susan F. Leitman,
Lynn R. Goldin,
Konrad Huppi, and
Stephen J. Chanock
From the Immunocompromised Host Section, Pediatric Oncology Branch,
the Genetic Epidemiology Branch, Division of Cancer Epidemiology and
Genetics, and the Laboratory of Genetics, National Cancer Institute,
and the Department of Transfusion Medicine, Clinical Center, National
Institutes of Health, Bethesda, MD.
Fc -receptors (FcR) provide a critical link between humoral and
cellular immunity. The genes of the low-affinity receptors for IgG and
their isoforms, namely, FcRIIa, FcRIIb, FcRIIIa, FcRIIIb,
and SH-FcRIIIb, are located in close proximity on chromosome 1q22.
Variant alleles may differ in biologic activity and a number of studies
have reported the frequencies of variant FcR alleles in both disease
and control populations. No large study has evaluated the possibility
of a nonrandom distribution of variant genotypes. We analyzed 395 normal individuals (172 African Americans [AA] and 223 Caucasians
[CA]) at the following loci: FcRIIa, FcRIIIa, and FcRIIIb,
including the SH-FcRIIIb. The genotypic distributions of FcRIIa,
FcRIIIa, and FcRIIIb conform to the Hardy-Weinberg law in each
group. There was no strong evidence that combinations of 2-locus
genotypes of the 3 loci deviated from random distributions in these
healthy control populations. The distribution of SH-FcRIIIb is
underrepresented in CA compared with AA (P < .0001) controls. A previously reported variant FcRIIb was not detected in 70 normal individuals, indicating that this allele, if it exists, is very rare
(<1%). In conclusion, we present data that should serve as the
foundation for the interpretation of association studies involving multiple variant alleles of the low-affinity FcR.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
L. G. Perez, M. R. Costa, C. A. Todd, B. F. Haynes, and D. C. Montefiori
Utilization of Immunoglobulin G Fc Receptors by Human Immunodeficiency Virus Type 1: a Specific Role for Antibodies against the Membrane-Proximal External Region of gp41
J. Virol.,
August 1, 2009;
83(15):
7397 - 7410.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. M. Cardarelli, M.-C. Moldovan-Loomis, B. Preston, A. Black, D. Passmore, T.-H. Chen, S. Chen, J. Liu, M. R. Kuhne, M. Srinivasan, et al.
In vitro and In vivo Characterization of MDX-1401 for Therapy of Malignant Lymphoma
Clin. Cancer Res.,
May 15, 2009;
15(10):
3376 - 3383.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Bruhns, B. Iannascoli, P. England, D. A. Mancardi, N. Fernandez, S. Jorieux, and M. Daeron
Specificity and affinity of human Fc{gamma} receptors and their polymorphic variants for human IgG subclasses
Blood,
April 16, 2009;
113(16):
3716 - 3725.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Lejeune, G. Thibault, D. Ternant, G. Cartron, H. Watier, and M. Ohresser
Evidence for Linkage Disequilibrium Between Fc{gamma}RIIIa-V158F and Fc{gamma}RIIa-H131R Polymorphisms in White Patients, and for an Fc{gamma}RIIIa-Restricted Influence on the Response to Therapeutic Antibodies
J. Clin. Oncol.,
November 20, 2008;
26(33):
5489 - 5491.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Musolino, N. Naldi, B. Bortesi, D. Pezzuolo, M. Capelletti, G. Missale, D. Laccabue, A. Zerbini, R. Camisa, G. Bisagni, et al.
In Reply
J. Clin. Oncol.,
November 20, 2008;
26(33):
5491 - 5492.
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. C. Willcocks, P. A. Lyons, M. R. Clatworthy, J. I. Robinson, W. Yang, S. A. Newland, V. Plagnol, N. N. McGovern, A. M. Condliffe, E. R. Chilvers, et al.
Copy number of FCGR3B, which is associated with systemic lupus erythematosus, correlates with protein expression and immune complex uptake
J. Exp. Med.,
July 7, 2008;
205(7):
1573 - 1582.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Musolino, N. Naldi, B. Bortesi, D. Pezzuolo, M. Capelletti, G. Missale, D. Laccabue, A. Zerbini, R. Camisa, G. Bisagni, et al.
Immunoglobulin G Fragment C Receptor Polymorphisms and Clinical Efficacy of Trastuzumab-Based Therapy in Patients With HER-2/neu-Positive Metastatic Breast Cancer
J. Clin. Oncol.,
April 10, 2008;
26(11):
1789 - 1796.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. N. Forthal, G. Landucci, J. Bream, L. P. Jacobson, T. B. Phan, and B. Montoya
Fc{gamma}RIIa Genotype Predicts Progression of HIV Infection
J. Immunol.,
December 1, 2007;
179(11):
7916 - 7923.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. Z. Alizadeh, G. Valdigem, M. J.H. Coenen, A. Zhernakova, B. Franke, A. Monsuur, P. L.C.M. van Riel, P. Barrera, T. R.D.J. Radstake, B. O. Roep, et al.
Association analysis of functional variants of the FcgRIIa and FcgRIIIa genes with type 1 diabetes, celiac disease and rheumatoid arthritis
Hum. Mol. Genet.,
November 1, 2007;
16(21):
2552 - 2559.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Jafarshad, M. H. Dziegiel, R. Lundquist, L. K. Nielsen, S. Singh, and P. L. Druilhe
A Novel Antibody-Dependent Cellular Cytotoxicity Mechanism Involved in Defense against Malaria Requires Costimulation of Monocytes Fc{gamma}RII and Fc{gamma}RIII
J. Immunol.,
March 1, 2007;
178(5):
3099 - 3106.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. S. Wang, J. R. Cerhan, P. Hartge, S. Davis, W. Cozen, R. K. Severson, N. Chatterjee, M. Yeager, S. J. Chanock, and N. Rothman
Common Genetic Variants in Proinflammatory and Other Immunoregulatory Genes and Risk for Non-Hodgkin Lymphoma
Cancer Res.,
October 1, 2006;
66(19):
9771 - 9780.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N.-K. V. Cheung, R. Sowers, A. J. Vickers, I. Y. Cheung, B. H. Kushner, and R. Gorlick
FCGR2A Polymorphism Is Correlated With Clinical Outcome After Immunotherapy of Neuroblastoma With Anti-GD2 Antibody and Granulocyte Macrophage Colony-Stimulating Factor
J. Clin. Oncol.,
June 20, 2006;
24(18):
2885 - 2890.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. E. Brown, M. D. Fallin, J. J. Goedert, R. Chen, D. Whitby, C. B. Foster, C. Lauria, A. J. Alberg, A. Messina, M. Montella, et al.
A Common Genetic Variant in FCGR3A-V158F and Risk of Kaposi Sarcoma Herpesvirus Infection and Classic Kaposi Sarcoma
Cancer Epidemiol. Biomarkers Prev.,
March 1, 2005;
14(3):
633 - 637.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Niwa, S. Hatanaka, E. Shoji-Hosaka, M. Sakurada, Y. Kobayashi, A. Uehara, H. Yokoi, K. Nakamura, and K. Shitara
Enhancement of the Antibody-Dependent Cellular Cytotoxicity of Low-Fucose IgG1 Is Independent of Fc{gamma}RIIIa Functional Polymorphism
Clin. Cancer Res.,
September 15, 2004;
10(18):
6248 - 6255.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. L. Gluck, D. Hurst, A. Yuen, A. M. Levine, M. A. Dayton, J. P. Gockerman, J. Lucas, K. Denis-Mize, B. Tong, D. Navis, et al.
Phase I Studies of Interleukin (IL)-2 and Rituximab in B-Cell Non-Hodgkin's Lymphoma: IL-2 Mediated Natural Killer Cell Expansion Correlations with Clinical Response
Clin. Cancer Res.,
April 1, 2004;
10(7):
2253 - 2264.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W.-K. Weng and R. Levy
Two Immunoglobulin G Fragment C Receptor Polymorphisms Independently Predict Response to Rituximab in Patients With Follicular Lymphoma
J. Clin. Oncol.,
November 1, 2003;
21(21):
3940 - 3947.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Cartron, L. Dacheux, G. Salles, P. Solal-Celigny, P. Bardos, P. Colombat, and H. Watier
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor Fcgamma RIIIa gene
Blood,
February 1, 2002;
99(3):
754 - 758.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. A. Trikalinos, F. B. Karassa, and J. P. A. Ioannidis
Meta-analysis of the association between low-affinity Fcgamma receptor gene polymorphisms and hematologic and autoimmune diseases
Blood,
September 1, 2001;
98(5):
1634 - 1636.
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. W. Press, J. P. Leonard, B. Coiffier, R. Levy, and J. Timmerman
Immunotherapy of Non-Hodgkin's Lymphomas
Hematology,
January 1, 2001;
2001(1):
221 - 240.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. M. Taylor, M. P. Reilly, A. D. Schreiber, P. Chien, J. R. Tuckosh, and S. E. McKenzie
Thrombosis and shock induced by activating antiplatelet antibodies in human Fcgamma RIIA transgenic mice: the interplay among antibody, spleen, and Fc receptor
Blood,
December 15, 2000;
96(13):
4254 - 4260.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. L. nbecher, C. B. Foster, S. Zhu, D. Venzon, S. M. Steinberg, K. Wyvill, J. A. Metcalf, S. S. Cohen, J. Kovacs, R. Yarchoan, et al.
Variant genotypes of Fcgamma RIIIA influence the development of Kaposi's sarcoma in HIV-infected men
Blood,
April 1, 2000;
95(7):
2386 - 2390.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. Shields, A. K. Namenuk, K. Hong, Y. G. Meng, J. Rae, J. Briggs, D. Xie, J. Lai, A. Stadlen, B. Li, et al.
High Resolution Mapping of the Binding Site on Human IgG1 for Fcgamma RI, Fcgamma RII, Fcgamma RIII, and FcRn and Design of IgG1 Variants with Improved Binding to the Fcgamma R
J. Biol. Chem.,
February 23, 2001;
276(9):
6591 - 6604.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
